The Expression of Activation Markers CD25 and CD69 Increases during Biologic Treatment of Psoriasis

Area of Science:

• Immunology
• Dermatology
• Cell Biology

Background:

• Cluster of differentiation (CD) 69 and CD25 are established lymphocyte activation markers.
• CD69, initially considered an early activation marker, demonstrates immunomodulatory functions.
• Both markers are found on various immune cells, including regulatory T cells and lymphocytes infiltrating inflamed tissues.

Purpose of the Study:

• To investigate the expression of CD69 and CD25 in peripheral blood mononuclear cells (PBMCs) of psoriasis patients.
• To compare marker expression between psoriasis patients and healthy controls.
• To evaluate the impact of biologic drug treatment on CD69 and CD25 levels in psoriasis.

Main Methods:

• Flow cytometry was employed to analyze PBMCs.
• Expression levels of CD69 and CD25 were quantified on different lymphocyte subsets.
• Patient cohorts included individuals with psoriasis (some on biologic therapy) and healthy controls.

Main Results:

• Psoriasis patients exhibited significantly higher CD3/CD69, CD8/CD69, and CD19/CD69 positive PBMCs compared to healthy controls.
• Elevated levels of CD3/CD69, CD4/CD69, CD19/CD69 positive PBMCs, and specific subset expressions (CD3/CD69, CD4/CD69, CD4/CD25, CD19/CD69) were observed in psoriasis patients before biologic therapy.
• Biologic treatment led to a significant increase in several CD69 and CD25 expressing cell populations.

Conclusions:

• The findings support a significant role for activation markers, particularly CD69, in the pathogenesis of psoriasis.
• Further research is needed to elucidate the precise significance of these markers in psoriasis, especially in the context of biologic treatments.
• CD69 and CD25 warrant further investigation as potential biomarkers or therapeutic targets in psoriasis management.